Drug Trial Radar · NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
363
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
May 1, 2028
Study completion Dec 15, 2028
Sponsor
- Lead sponsor
- OSE ImmunotherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Exystat; GeneDx
- First posted
- Jun 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Conditions
- Patients With Non-Small Cell Lung Cancer
Interventions
OSE2101Drug
OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumor associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified in Montanide ISA 51TM adjuvant.
DocetaxelDrug
Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.
NGS HLAA2 assayDevice
Amp-HLA-A-CDx Tedopi for amplification of human genomic DNA (gDNA), LFK-CDx Tedopi kit (library full kit) for library preparation, NGSengine-CDx Tedopi software for analysis of NGS data files.
Primary outcomes
What the sponsor says the trial is designed to measure.
- OS defined as time from randomization to deathTime frame: From randomization date through study completion, an average of 3 years
Locations
207 sites in 14 countries. Site status is shown where the registry gives one.
Clinical Research Advisors, LLC
Beverly Hills, California · Recruiting
Clinical Research Advisors - Encino
Encino, California · Active not recruiting
Clinical Research Advisors - West Hollywood
Los Angeles, California · Active not recruiting
Clinical Research Advisors - Korea Town
Los Angeles, California · Active not recruiting
SCL Health - Saint Joseph Hospital Cancer Center
Littleton, Colorado · Withdrawn
Lutheran Medical Center - Cancer Centers of Colorado
Wheat Ridge, Colorado · Recruiting
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut · Recruiting
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Comprehensive Hematology Oncology - Bradenton Clinic
Bradenton, Florida · Active not recruiting
Comprehensive Hematology Oncology - Brandon Clinic
Brandon, Florida · Active not recruiting
Cancer Specialists of North Florida - Fleming Island
Fleming Island, Florida · Recruiting
Cancer Specialists of North Florida - Riverside
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida Southside
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida - Northside
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida - Southpoint
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida - Baptist South
Jacksonville, Florida · Active not recruiting
Cancer Specialists of North Florida
Jacksonville Beach, Florida · Recruiting
Comprehensive Hematology Oncology - Largo Clinic
Largo, Florida · Active not recruiting
Cancer Specialists of North Florida - Beaches
Neptune Beach, Florida · Active not recruiting
Comprehensive Hematology Oncology - Palm Harbor Clinic
Palm Harbor, Florida · Active not recruiting
Cancer Specialists Of North Florida - St. Augustine
Saint Augustine, Florida · Recruiting
Comprehensive Hematology Oncology - Bayfront Clinic
St. Petersburg, Florida · Active not recruiting
Comprehensive Hematology Oncology
St. Petersburg, Florida · Recruiting
Comprehensive Hematology Oncology - Trinity Clinic
Trinity, Florida · Recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
Alliance for Multispecialty Research (AMR) - Kansas City Oncology
Merriam, Kansas · Withdrawn
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana · Active not recruiting
Pontchartrain Cancer Center - Covington Office
Covington, Louisiana · Recruiting
Pontchartrain Cancer Center - Hammond Office
Hammond, Louisiana · Recruiting
Ascension Saint Agnes Hospital
Baltimore, Maryland · Recruiting
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts · Recruiting
Nebraska Hematology-Oncology - Revive Research Institute LLC
Lincoln, Nebraska · Recruiting
New York Cancer & Blood Specialists - Babylon Medical Oncology
Babylon, New York · Active not recruiting
Optum Medical Care - Carmel/Brewster Campus
Brewster, New York · Terminated
Brooklyn Radiation Oncology
Brooklyn, New York · Terminated
Optum Medical Care - Fishkill Westage Campus
Fishkill, New York · Terminated
Clinical Research Alliance
Lake Success, New York · Terminated
Optum Medical Care - Mount Kisco Campus 90
Mount Kisco, New York · Terminated
New York Cancer & Blood Specialists - New Hyde Park
New Hyde Park, New York · Recruiting
Optum Hematology Oncology - Lake Success
New Hyde Park, New York · Terminated
Showing 40 of 207 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.